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Introduction
In adult populations, atrial fibrillation (AF) is the major 
arrhythmia and successful treatment rates are low [1]. In 
recent years, left atrial appendage occlusion (LAAO) has 
become an alternative method for stroke prevention in 
patients in whom oral anticoagulation (OAC) is ineffec-
tive or contraindicated or in patients with life-threaten-
ing complications [2, 3]. Previous studies have demon-
strated that the LAAO procedure is safe and effective in 
the prevention of thromboembolic events, including in 
high risk patients [4–10]. 
In the medical market, there are a number of avail-
able devices including endocardial and epicardial devices 
[4, 5, 9]. However, in some cases, the anatomy of the left 
atrial appendage (LAA) may constitute a contraindication 
to implantation of these devices. The LAmbre device is 
a novel system, designed especially for LAA closure when 
problematic morphology is present [11, 12]. 
Aim
Herein, we present the first use of the LAmbre device 
in Poland in patients with AF.
Material and methods
A retrospective, single-center study was performed in 
24 consecutive patients with non-valvular AF, who under-
went LAAO with the LAmbre device (Lifetech Scientific 
Corp., Shenzhen, China) between 2016 and 2018 (Figure 1). 
The LAmbre occluder system was previously described 
[13]. LAmbre device selection was based on operators’ de-
cision. All procedures were performed under general an-
esthesia. Patient characteristics are presented in Table I. 
The LAA anatomy was assessed with computed tomogra-
phy angiography before each procedure. Oral anticoagu-
lation therapy was discontinued and unfractionated hep-
arin was used during the procedure. After the procedure, 
aspirin (75 mg/dose/day) and clopidogrel (75 mg/dose/
day) for 6 months were recommended in each patient. 
Leak was defined as the presence of flow from the left 
atrium to the LAA < 3 mm [14].
Follow-up visits, including transesophageal echocar-
diography, were performed at 3 and 6 months post-pro-
cedure. Data on mortality, causes of mortality and seri-
ous adverse events (SAE) were collected.
Statistical analysis
Data are expressed as mean ± standard deviation or 
median (interquartile range; Q1 – 25th percentile and Q3 
– 75th percentile), unless otherwise stated. Categorical 
variables were expressed as counts and percentages. 
Results
All procedures were successfully completed with no 
perioperative complications. The LAAO procedure or de-
vice related mortality was 0%. The mean time for the 
procedure was 62.92 ±14.21 min. Eleven different sizes 
of occluder were implanted during the procedures, de-
pending on the size and shape of the left atrial append-
age. The choice of device size was made by the operator 
during the procedure based on intraprocedural transe-
sophageal echocardiography (TEE) examination. There 
was a  100% success rate with no complications. No 
post-procedural leaks were observed. Half of the patients 
were discharged from hospital on the second or third day 
following the procedure. 
The overall follow-up was 349 months. During the fol-
low-up period, there were 4 (16.7%) deaths; 1 case with 
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acute exacerbation of chronic renal failure complicated 
by heart failure (5 months after the procedure); 1 case 
of out-of-hospital cardiac arrest (5 months after the pro-
cedure), 1 case of post neurosurgery complications due 
to cerebral artery aneurysm (15 months after the proce-
dure) and in 1 case, the cause of death was unknown. 
There were no deaths connected to the procedure. Gas-
trointestinal bleeding were observed in 2 (8.34%) cases. 
There was 1 (4.17%) case of transient ischemic attack 
and 1 (4.17%) case of stroke, 16 and 3 months after the 
procedure, respectively. In both cases control TEE exam-
ination showed no device thrombus. In the remaining 
patients follow-up TEE showed no device thrombi or LAA 
leaks (Table I). 
Discussion
We present the first results in Poland of the LAAO 
procedure with LAmbre devices, with a  100% success 
rate and with no perioperative complications. From our 
initial experience, implantation is associated with a high 
success rate and good clinical outcomes.
Our results are similar to the most popular endocar-
dial devices such as the Watchman or Amplatzer [4, 15]. 
Surprisingly, in our study, there was a  larger number of 
postprocedural bleeding episodes, which were observed 
in 8.34% of patients, compared to other endocardial tri-
als [4, 15]. However, in our study, patients had a very high 
risk of bleeding (HAS-BLED score 4) and, in more than 
60% of patients, the indication for LAAO was previous 
bleeding episodes. Of note, all bleeding episodes were 
among patients who were receiving antiplatelet therapy, 
and none were receiving OAC.
The observed mortality rate (16.6%) was also higher 
than that reported in other endocardial device trials [4, 
15]. However, none of the deaths were related to the pro-
cedure. Boersma et al. observed a 9.8% mortality rate at 
12 months of observation in a Watchman device trial [4]. 
Importantly, all deceased patients were free of thrombus 
on the occluder and from postprocedural leak at 3-month 
and 6-month visits. Additionally, no device thrombi were 
observed, despite not receiving OAC, even in transient 
ischemic attack (TIA) and stroke patients. Similar data 
were obtained by Huang et al. [14].
The LAA morphology, including the LAA shape, osti-
um width and depth, plays a  critical role in the choice 
of device. The most popular devices such as the Watch-
man, with its umbrella-like shape, should be avoided in 
Figure 1. LAmbre occluder connected to the sheath (A), fluoroscopy (B), transesophageal echocardiography (C)  
and 3D echocardiography (D) of the LAmbre occluder after release and correctly placed in the left atrial ap-
pendage
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shallow or multilobar LAAs. The second most common-
ly used device, the Amplatzer ACP, should be avoided in 
shallow LAAs because of the relatively proximal position 
of LAA implantation [13]. The LAmbre device is available 
in a larger range of device sizes (16–36 mm) compared to 
the Watchman (21–30 mm) and ACP (16–34 mm) devic-
es. It is also highly adaptive to many LAA sizes due to its 
smaller umbrellas with larger covers. Therefore, the larg-
er choice of sizes and favorable device properties may 
make the LAmbre device more suitable for complex LAA 
anatomies, such as chicken wing or shallow LAA [13].
Conclusions
The LAAO procedure with the LAmbre device is as-
sociated with a high success rate and good short term 
clinical results.
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